CTOs on the Move

Turning Point Therapeutics

www.tptherapeutics.com

 
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Ed Gemo
SVP/CIO Profile

Funding

Turning Point Therapeutics raised $45M on 05/23/2017
Turning Point Therapeutics raised $80M on 10/19/2018
Turning Point Therapeutics raised $202.5M on 09/16/2019
Turning Point Therapeutics raised $373.8M on 05/18/2020

Similar Companies

Demetrix

Nature is a rich source of ingredients. Inconsistent quality and supply, along with inaccessibility of rare substances, mean it`s not always an ideal source to meet the world`s needs.

OncoArendi Therapeutics

OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of innovative small molecule drugs for treatment of respiratory diseases and cancer.

kinetix pharm

kinetix pharm is a Medford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Botanix Pharmaceuticals

Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.

Frontier BioSciences

Frontier BioSciences is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.